EMA’s PRAC to review Xeljanz and recommends fenspiride withdrawl
The committee has announced its latest meeting highlights.
Read More
Tag: fenspiride
EMA suspends fenspiride medicines due to heart rhythm risks
The EMA has announced an EU-wide suspension of fenspiride medicines due to a potential risk of heart rhythm problems.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
